Anti-inflammatory diets for obesity and diabetes

Journal of the American College of Nutrition

Volumn 28, Issue , 2009, Pages 482S-491S

  Sears, Barry ^a  

^a The Inflammation Research Foundation   (United States)

Author keywords

Anti inflammatory diet; Obesity; Silent inflammation; Type 2 diabetes

Indexed keywords

ARACHIDONIC ACID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIHOMO GAMMA LINOLENIC ACID; GAMMA LINOLENIC ACID; ICOSAPENTAENOIC ACID; INSULIN; INTERLEUKIN 6; LINOLEIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; TUMOR NECROSIS FACTOR; VEGETABLE OIL;

ADIPOCYTE; ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; CALORIC RESTRICTION; CANNED FOOD; CARBOHYDRATE INTAKE; COOKING; DIETARY INTAKE; FATTY ACID METABOLISM; FOOD COMPOSITION; FRUIT; GLYCEMIC CONTROL; HUMAN; INFLAMMATION; MEDITERRANEAN DIET; METABOLIC SYNDROME X; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN INTAKE; RAW FOOD; REVIEW; ROUX Y ANASTOMOSIS; STOMACH BYPASS; VEGETABLE;

ADIPOSE TISSUE; ANIMALS; DIABETES MELLITUS, TYPE 2; DIET; HUMANS; INFLAMMATION; METABOLIC SYNDROME X; OBESITY;

EID: 77951553393     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2009.10718115     Document Type: Article

References (119)

1. Hossain P, Kawar B, Nahas ME: Obesity and diabetes in the developing world. N Engl J Med 356:213–216, 2007.
2. Sears B: “The OmegaRx Zone.” New York: Regan Books, 2002.
3. Sears B: “The Anti-Inflammation Zone.” New York: Regan Books, 2005.
4. Sears B: “Toxic Fat.” Nashville: Thomas Nelson, 2008.
5. Tall AR: C-Reactive protein reassessed. N Engl J Med 350:1450–1452, 2004.
6. Campbell B, Badrick T, Flatman R, Kanowshi D: Limited clinical utility of high-sensitivity plasma C-reactive protein assays. Ann Clin Biochem 39:85–88, 2002.
7. Campbell B, Flatman R, Badrick T, Kanowshi D: Problems with high-sensitivity C-reactive protein. Clin Chem 49:201, 2003.
8. Drewnowski A, Specter SE: Poverty and obesity: the role of energy density and energy costs. Am J Clin Nutr 79:6–16, 2004.
9. Jenkins DJ, Wolever TM, Taylor RH, Barker H, Fielden H, Baldwin JM, Bowling AC, Newman HC, Jenkins AL, Goff DV: Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr 34:362–366, 1981.
10. Ludwig DS: The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA 287:2414–2423, 2002.
11. Martinelli N, Girelli D, Malerba G, Guarini P, Illig T, Trabetti E, Sandri M, Friso S, Pizzolo F, Schaeffer L, Heinrich J, Pignatti PF, Corrocher R, Olivieri O: FADS genotypes and desaturase activity estimated by the ratio of arachidonic acid to linoleic acid are associated with inflammation and coronary artery disease. Am J Clin Nutr 88:941–949, 2008.
12. Darmon N, Darmon M, Maillot M, Drewnowski A: A nutrient density standard for vegetables and fruits: nutrients per calorie and nutrients per unit cost. J Am Diet Assoc 105:1881–1887, 2005.
13. Drewnowski A, Darmon N, Briend A: Replacing fats and sweets with vegetables and fruits—a question of cost. Am J Public Health 94:1555–1559, 2004.
14. Monsivais P, Drewnowski A: The rising cost of low-energydensity foods. J Am Diet Assoc 107:2071–2076, 2007.
15. Brenner RR: Nutrition and hormonal factors influencing desaturation of essential fatty acids. Prog Lipid Res 20:41–48, 1982.
16. el Boustani S, Gausse JE, descomps B, Monnier L, Mendy F, Crastes de Paulet A: Direct in vivo characterization of the delta-5 desaturase activity in humans by deuterium labeling: effect of insulin. Metabolism 38:315–321, 1989.
17. Pelikonova T, Kohout M, Base J, Stefka Z, Kovar L, Kerdova L, Valek J: Effect of acute hyperinsulinemia on fatty acid composition of serum lipid in non–insulin dependent diabetics and healthy men. Clin Chem Acta 203:329–337, 1991.
18. Brenner RR: Hormonal modulation of delta-6 and delta-5 desaturases. Prostaglandins Leukot Essent Fatty Acids 68:151–162, 2003.
19. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL: Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 196:1025–1037, 2002.
20. Serhan CN, Arita M, Hong S, Gotlinger K: Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids 39:1125–1132, 2004.
21. Serhan CN: Novel omega-3 derived local mediators in antiinflammation and resolution. Pharmacol Therapeut 105:7–21, 2005.
22. Serhan CN: Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 25:101–137, 2007.
23. Simopoulos AP: Essential fatty acids in health and chronic disease. Am J Clin Nutr 70:560S–569S, 1999.
24. Massiera F, Saint-Marc P, Sedoux J, Murata T, Kobayshi T, Marumiya S, Guesnet P, Amri E-Z, Megrel R, Ailhaud G: Arachidonic acid and prostacylin signaling promote adipose tissue development: a human health concern? J Lipid Res 44:271–279, 2003.
25. Mazid MA, Chowdhury AA, Nagao K, Nishimura K, Jisaka M, Nagaya T, Yokota K: Endogenous 15-deoxy-delta(12,14)-prostaglandin J(2) synthesized by adipocytes during maturation phase contributes to upregulation of fat storage. FEBS Lett 580:6885–6890, 2006.
26. Savva SC, Chadjigeorgiou C, Hatzis C, Kyriakakis M, Tsimbinos G, Tornaritis M, Kafatos A: Association of adipose tissue arachidonic acid content with BMI and overweight status in children from Cyprus and Crete. Br J Nutr 91:643–649, 2004.
27. Hollenbeck C, Reaven GM: Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab 64:1169–1173, 1987.
28. National Center for Health Statistics: “Health, United States, 2007, With Chartbook on Trends in the Health of Americans.” Hyattsville, MD: NCHS, 2007.
29. Maeda K, Uysal KT, Makowski L, Gorgun CZ, Atsumi G, Parker RA, Bruning J, Hertzel AV, Bernlohr DA, Hotamisligil GS: Role of the fatty acid binding protein mal1 in obesity and insulin resistance. Diabetes 52:300–307, 2003.
30. Bonen A, Tandon NN, Glatz JFC, Luiken JJFP, Heigenhauser GJF: The fatty acid transporter FAT/CD36 is upregulated in subcutaneous and visceral adipose tissues in human obesity and type 2 diabetes. Int J Obesity 30:877–883, 2006.
31. Erbay E, Cao H, Hotamisligil GS: Adipocyte/macrophage fatty acid binding proteins in metabolic syndrome. Curr Atheroscler Rep 9:2222–2229, 2007.
32. Duruhashi M, Fucho R, Gorgun CZ, Tuncman G, Cao H, Hotamisligil GS: Adipocyte/macrophage fatty acid binding proteins contribute to metabolic deterioration through actions in macrophages and adipocytes in mice. J Clin Invest 118:2640–2650, 2008.
33. Botion LM, Green A: Long-term regulation of lipolysis and hormone-sensitive lipase by insulin and glucose. Diabetes 48:1691–1697, 1999.
34. Haemmerle G, Zimmermann R, Zechner R: Letting lipids go: hormone-sensitive lipase. Curr Opin Lipidol 14:289–297, 2003.
35. Yeaman SJ: Hormone-sensitive lipase—new roles for an old enzyme. Biochemistry 379:11–22, 2004.
36. Taubes G: “Good Calories, Bad Calories.” New York: Alfred Knopf, 2007.
37. van den Hoek AM, Teusink B, Voshol PJ, Havekes LM, Romijin JA, Pijl H: Leptin deficiency per se dictates body composition and insulin action in ob/ob mice. J Neuroendocrinol 20:120–127, 2008.
38. Kotidis EV, Koliakos GG, Baltzopoulos VG, Ioannidis KN, Yovos JG, Papavramidis ST: Serum ghrelin, leptin and adiponectin levels before and after weight loss: comparison of three methods of treatment—a prospective study. Obes Surg 16:1425–1432, 2006.
39. Santosa S, Demonty I, Lichtenstein AH, Cianflone K, Jones PJ: An investigation of hormone and lipid associations after weight loss in women. J Am Coll Nutr 26:250–258, 2007.
40. Williams ES, Baylin A, Campos H: Adipose tissue arachidonic acid and the metabolic syndrome in Costa Rican adults. Clin Nutr 26:474–482, 2007.
41. Aldamiz-Echevarria L, Prieto JA, Andrade F, Elorz J, Sanjurjo P, Rodriguez Soriano J: Arachidonic acid content in adipose tissue is associated with insulin resistance in healthy children. J Pediatr Gastroenterol Nutr 44:77–83, 2007.
42. McLaughlin T, Sherman A, Tsao P, Gonzalez O, Yee G, Lamendola C, Reaven GM, Cushman SW: Enhanced proportion of small adipose cells in insulin-resistant vs. insulin-sensitive obese individuals implicates impaired adipogenesis. Diabetologia 50:1707–1715, 2007.
43. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796–1808, 2003.
44. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821–1830, 2003.
45. Wellen KE, Hotamisligil GS: Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112:1785–1788, 2003.
46. Festa A, D’Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome. Circulation 102:42–47, 2000.
47. Ruan H, Lodish HF: Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 14:447–455, 2003.
48. Pompeia C, Lima T, Curi R: Arachidonic acid cytotoxicity: can arachidonic acid be a physiological mediator of cell death? Cell Biochem Funct 21:97–104, 2003.
49. Permana PA, Menge C, Reaven PD: Macrophage-secreted factors induce adipocyte inflammation and insulin resistance. Biochem Biophys Res Commun 341:507–514, 2006.
50. Shoelson SE, Lee J, Goldfine AB: Inflammation and insulin resistance. J Clin Invest 116:1793–1801, 2006.
51. Neels JG, Olefsky JM: Inflamed fat: what starts the fire? J Clin Invest 116:33–35, 2006.
52. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, Fortier M, Greenberg AS, Obin MS: Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46:2347–2355, 2005.
53. Lee YH, Pratley RE: The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep 5:70–75, 2005.
54. Yudkin JS: Inflammation, obesity, and the metabolic syndrome. Horm Metab Res 39:707–709, 2007.
55. Heilbronn LK, Campbell LV: Adipose tissue macrophages, lowgrade inflammation and insulin resistance in human obesity. Curr Pharm Res 14:1225–1230, 2008.
56. de Luca C, Olefsky JM: Inflammation and insulin resistance. FEBS Lett 582:97–105, 2008.
57. Kinstcher U, Hartge M, Hess K, Foryst-Ludwig A, Cleminz M, Wabitsch M, Fischer-Posovszky P, Barth TF, Dragun D, Skurk T, Hauner H, Bluher M, Unger T, Wolf AM, Knippschild U, Homback V, Marx N: T-Lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol 28:1304–1310, 2008.
58. Kahn S, Hull RL, Utzschneider KM: Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840–846, 2007.
59. Todoric J, Löffler M, Huber J, Bilban M, Reimers M, Kadl A, Zeyda M, Waldhäusl W, Stulnig TM: Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. Diabetologia 49:2109–2119, 2006.
60. Huber J, Loffler M, Bilban M, Reimers M, Kadl A, Todoric J, Zeyda M, Geyeregger R, Schreiner M, Weichhart T, Leitinger N, Waldhausl W, Stulnig TM: Prevention of high-fat diet-induced adipose tissue remodeling in obese diabetic mice by n-3 polyunsaturated fatty acids. Int J Obes 31:1004–1013, 2007.
61. Unger RH: Weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 144:5159–5165, 2003.
62. Unger RH: Lipotoxic diseases. Ann Rev Med 53:319–336, 2002.
63. Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, Sowers MR: The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med 168:1617–1624, 2008.
64. Karelis AD, Faraj M, Bastard JP, St-Pierre DH, Brochu M, Prud’homme D, Rabasa-Lhoret R. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab 90:4145–4150, 2005.
65. Aguilar-Salinas CA, Garcia EG, Robles L, Riano D, Ruiz-Gomez DG, Garcia-Ulloa AC, Melgarejo MA, Zamora M, Guillen-Pineda LE, Mehta R, Canizales-Quinteros S, Tusie Luna MT, Gomez-Perez FJ: High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab 93:4075–4079, 2008.
66. Unger RH, Zhou YT: Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes 50:S118–S121, 2001.
67. Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, Schraw T, Durand JL, Li H, Li G, Jelicks LA, Mehler MF, Hui DY, Deshaies Y, Shulman GI, Schwartz GJ, Scherer PE: Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 117:2621–2637, 2007.
68. Levy P, Fried M, Santini F, Finer N: The comparative effects of bariatric surgery on weight and type 2 diabetes. Obes Surg 17:1248–1256, 2007.
69. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lonroth H, Naslund I, Olbers T, Stenlof K, Torgerson J, Agren G, Carlsson LM: Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357:741–752, 2007.
70. le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A, Lonroth H, Fandriks L, Ghatei MA, Bloom SR, Olbers T: Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 246:780–785, 2007.
71. le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, Shurey S, Ghatei MA, Patel AG, Bloom SR: Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weigh loss, and improve metabolic parameters. Ann Surg 243:108–114, 2006.
72. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559, 2008.
73. Ebstein W: Zur therapie des diabetes mellitus, insbesondere über die anwendung des salicylsauren natron bei demselben. Berliner Klinische Wochenschrift 13:337–340, 1876.
74. Williamson RT: On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br Med J i:760–762, 1901.
75. Reid J, MacDougall AI, Andrews MM: On the efficacy of salicylate in treating diabetes mellitus. Br Med J ii:1071–1074, 1957.
76. Djuric Z, Vanloon G, Radakovich K, Dilaura NM, Heibrun LK, Sen A: Design of a Mediterranean exchange list diet implemented by telephone counseling. J Am Diet Assoc 108:2059–2065, 2008.
77. Batterham RL, Heffron H, Kapoor S, Chivers JE, Chandarana K, Herzog H, le Roux CW, Thomas EL, Bell JD, Withers DJ: Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 4:223–233, 2006.
78. Lee JY, Ye J, Gao Z, Youn HS, Lee WH, Zhao L, Sizemore N, Hwang DH: Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J Biol Chem 278:37041–37051, 2003.
79. Lee JY, Zhao L, Youn HS, Weatherill AR, Tapping R, Feng L, Lee WH, Fitzgerald KA, Hwang DH: Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J Biol Chem 279:16971–16999, 2004.
80. Suganami T, Tanimoto-Koyama K, Nishida J, Itoh M, Yuan X, Mizuarai S, Kotani H, Yamaoka S, Miyake K, Aoe S, Kamei Y, Ogawa Y: Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid–induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol 27:84–91, 2007.
81. Kennedy A, Marinez K, Chuang C-C, LaPoint K, McIntosh M: Saturated fatty acid-mediated inflammation and insulin resistance in the adipose tissue. J Nutr 139:1–4, 2009.
82. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR 4 links innate immunity and fatty acid–induced insulin resistance. J Clin Invest 116:3015–3025, 2006.
83. Neschen S, Morino K, Rossbacher JC, Pongratz RL, Cline GW, Sono S, Gillum M, Shulman GI: Fish oil regulates adiponectin secretion by a peroxisome proliferator–activated receptor–gammadependent mechanism in mice. Diabetes 55:924–928, 2006.
84. Itoh M, Suganami T, Satoh N, Tanimoto-Koyama K, Yuan X, Tanaka M, Kawano H, Yano T, Aoe S, Takeya M, Shimatsu A, Kuzuya H, Kamei Y, Ogawa Y: Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol 27:1918–1925, 2007.
85. Ramel A, Marinez A, Kiely M, Morais G, Bandarra NM, Thordottir I: Beneficial effects of long-chain n-3 fatty acids included in an energy-restricted diet on insulin resistance in overweight and obese European young adults. Diabetologia 51:1261–1268, 2008.
86. Lu JY, Huang KC, Chang LC, Huang YS, Chi YC, Su TC, Chen CL, Yang WS: Adiponectin: a biomarker of obesity-induced insulin resistance in adipose tissue and beyond. J Biomed Sci 15:565–576, 2008.
87. Ludwig DS, Majzoub JA, Al-Zahrani A, Dallal GE, Blanco I, Roberts SB: Dietary high glycemic index foods, overeating, and obesity. Pediatrics 103:E26, 1999.
88. Agus MS, Swain JF, Larson CL, Eckert EA, Ludwig DS: Dietary composition and physiological adaptation to energy restriction. Am J Clin Nutr 71:901–907, 2000.
89. Dunesnil JG, Turgeon J, Tremblay A, Poirer P, Gilbert M, Gagnon L, St-Pierre S, Garneau C, Lemieux I, Pascot A, Bergeron J, Despres JP: Effect of a low-glycaemic index–low-fat–high protein diet on the atherogenic metabolic risk profile of abdominally obese men. Br J Nutr 86:557–568, 2001.
90. Layman DK, Shiue H, Sather C, Erickson DJ, Baum J: Increased dietary protein modifies glucose and insulin homeostasis in adult women during weight loss. J Nutr 133:405–410, 2003.
91. Layman DK, Boileau RA, Erickson DJ, Painter JE, Shiue H, Sather C, Christou DD: A reduced ratio of dietary carbohydrate to protein improves body composition and blood lipid profiles during weight loss in adult women. J Nutr 133:411–417, 2003.
92. Wolfe BM, Piche LA: Replacement of carbohydrate by protein in a conventional-fat diet reduces cholesterol and triglyceride concentrations in healthy normolipidemic subjects. Clin Invest Med 22:140–148, 1999.
93. Fontani G, Corradeschi F, Felici A, Alfatti F, Bugarini R, Fiaschi AI, Cerretani D, Montorfano G, Rizzo AM, Berra B: Blood profiles, body fat and mood state in healthy subjects on different diets supplemented with omega-3 polyunsaturated fatty acids. Eur J Clin Invest 35:499–507, 2005.
94. Nuttall FQ, Gannon MC, Saeed A, Jordan K, Hoover H: The metabolic response of subjects with type 2 diabetes to a highprotein, weight-maintenance diet. J Clin Endocrinol Metab 88:3577–3583, 2003.
95. Gannon MC, Nuttall FQ, Saeed A, Jordan K, Hoover H. An increase in dietary protein improves the blood glucose response in persons with type 2 diabetes. Am J Clin Nutr 78:734–741, 2003.
96. Ebbeling CB, Leidig MM, Feldman HA, Lovesky MM, Ludwig DS: Effects of a low-glycemic load vs low-fat diet in obese young adults: a randomized trial. JAMA 297:2092–2102, 2007.
97. Pittas AG, Das SK, Hajduk CL, Golden J, Saltzman E, Stark PC, Greenberg AS, Roberts SB: A low-glycemic load diet facilitates greater weight loss in overweight adults with high insulin secretion but not in overweight adults with low insulin secretion in the CALERIE Trial. Diabetes Care 28:2939–2941, 2005.
98. Pereira MA, Swain J, Goldfine AB, Rifai N, Ludwig DS: Effects of a low-glycemic load diet on resting energy expenditure and heart disease risk factors during weight loss. JAMA 292:2482–2490, 2004.
99. Joslin Diabetes Research Center Dietary Guidelines. Accessed at: www.joslin.org/Files/Nutrition_Guideline_Graded.pdf
100. Sears B: “The Zone.” New York: Regan Books, 1995.
101. Wing RR, Hill JO: Successful weight loss maintenance. Ann Rev Nutr 21:323–341, 2001.
102. Markovic TP, Jenkins AB, Campbell LV, Furler SM, Kraegen EW, Chishol DJ: Determinants of glycemic responses to diet restriction and weight loss in obesity and NIDDM. Diabetes Care 21:687–694, 1998.
103. Zhang X, Zhang G, Zhang H, Karin M, Bai H, Cai D: Hypothalamic IKKB/NK-kappa B and ER stress link overnutrition to energy imbalance and obesity. Cell 135:61–73, 2008.
104. le Roux CW, Batterham RL, Aylwin SJB, Patterson M, Borg CM, Wynne KJ, Ken A, Vencent RP, Cardiner J, Chatei MA, Bloom SR: Attenuated peptide YY release in obese subjects is associated with reduce satiety. Endocrinology 147:3–8, 2006.
105. Young AA: Obesity: a peptide YY–deficient, not peptide YY–resistant, state. Endocrinology 147:1–2, 2006.
106. Boey D, Heibronn L, Sanisbury A, Laybutt R, Kriketos A, Herzog H, Campbell LV: Low serum PYY is linked to insulin resistance in first-degree relatives of subjects with type 2 diabetes. Neuropeptides 40:317–324, 2006.
107. Viardot A, Heilbronn LK, Herzog H, Gregersen S, Campbell LV: Abnormal postprandial PYY responses in insulin sensitive nondiabetic subjects with a strong family history of type 2 diabetes. Int J Obesity 32:943–948, 2008.
108. Yoon JH, Baek SJ: Molecular targets of dietary polyphenols with anti-inflammatory properties. Yonsei Med J 46:585–596, 2005.
109. Scalbert A, Johnson IT, Saltmarsh M: Polyphenols: antioxidants and beyond. Am J Clin Nutr 81:215S–217S, 2005.
110. Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, Wierzbicki M, Verbeuren TJ, Cohen RA: Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor–deficient mice. Diabetes 55:2180–2191, 2006.
111. Viollet B, Mounier R, Leclerc J, Yazigi A, Foretz M, Andreelli F: Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders. Diabetes Metab 33:395–402, 2007.
112. Winder WW, Thomson DM: Cellular energy sensing and signaling by AMP-activated protein kinase. Cell Biochem Biophys 47:332–347, 2007.
113. Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WG, Schlattner U, Neumann D, Brownlee M, Freeman MB, Goldman MH: Activation of the AMP-activated protein kinase by the antidiabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem 279:43940–43951, 2004.
114. Watanabe S, Doshi M, Hamazaki T: n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonylglycerol level in mice. Prostaglandin Leukot Essent Fatty Acids 69:51–59, 2003.
115. Ambring A, Johansson M, Axelsen M, Gan L, Strandvik B, Friberg P: Mediterranean-inspired diet lowers the ratio of serum phospholipids n-6 to n-3 fatty acids, the number of leukocytes and platelets, and vascular endothelial growth factor in healthy subjects. Am J Clin Nutr 83:575–581, 2006.
116. Trichopoulou A, Costacou T, Bamia C, Trichopoulos D: Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med 348:2599–2608, 2003.
117. Vioque J, Weinbrenner T, Castello A, Asensio L, Garcia de la Hera M: Intake of fruits and vegetables in relation to 10-year weight gain among Spanish adults. Obesity 16:664–670, 2008.
118. Martinez-Gonzalez MA, De La Fuente-Arrillage C, Nunez-Cordoba JM, Basterra-Gortari FJ, Beunza JJ, Vazquez Z, Benito S, Tortosa A, Bes-Rastrollo M: Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study. BMJ 336:1348–1351, 2008.
119. Mitrou PN, Kipnis V, Thiebaut AC, Reedy J, Subar AF, Wirfalt E, Flood A, Mouw T, Hollenbeck AR, Leitzmann MF, Schatzkin A: Mediterranean dietary pattern and prediction of all-cause mortality in a US population: results from the NIH-AARP Diet and Health Study. Arch Intern Med 167:2461–2468, 2007.